NCT02599194 · REGISTRY CONDITION SEARCH

18F-FSPG PET/CT for Cancer Patients on Therapy

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2019-01-03

The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Change From Baseline in Standard Uptake Value Maximum (SUVmax) Post-treatment

→

outcome · POSTED

Number of Treatment-Related Adverse Events

→

outcome · POSTED

Change From Baseline in Lesion Size Post-treatment, by 18F-FSPG or 18F-FDGs

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Written informed consent * Able to complete a PET/CT scan without the use of sedation * Females: * Of childbearing potential must: * Not be nursing * Have a negative serum pregnancy test documented within 48 hours prior to administration of 18F FSPG PET/CT * Not of childbearing potential must be: * Physiologically postmenopausal (cessation of menses for more than 1 year) * Surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy) * Histologically confirmed cancer that is advanced; metastatic; or otherwise not suitable for surgical resection with curative intent * Scheduled to begin therapy * The time interval between 18F FSPG PET/CT and standard of care imaging (ie, 18F FDG PET/CT, diagnostic CT, or MRI) should be within 4 weeks (exceptions will be allowed for 6 weeks, if there are no other options) * Ideally, there should be no chemotherapy, radiotherapy, or immune/biologic therapy or biopsy between other imaging (PET/CTs, MRI, or diagnostic CTs) and 18F FSPG PET/CT scheduled or performed (exceptions by investigator discretion) * No clinically relevant deviations in renal function (serum creatinine \> grade 2 Common Terminology Criteria for Adverse Events \[CTCAE\] version 4.0); maximal interval between confirmation of renal function and injection of 18F FSPG is 1 week Exclusion Criteria: * Scheduled for surgery and/or another invasive procedure (except biopsy) within the time period of 1 month prior to 18F FSPG administration * Known sensitivity to 18F FSPG or components of the preparation * Investigator precludes participation for scientific reasons, for reasons of compliance, or for reasons of the patient's safety
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.
intervention Names
Drug: 18F-FSPG
Drug: 18F-FDG
label
18F-FSPG and 18F-FDG Intragroup Comparision
type
EXPERIMENTAL

interventions

arm Group Labels
18F-FSPG and 18F-FDG Intragroup Comparision
description
Administered intravenously (IV)
name
18F-FSPG
other Names
18F-labeled (S)-4-(3-[18F]-fluoropropyl)-L-glutamic acid
18F-labeled (4S)-4-(3-[18F]-fluoropropyl)-L-glutamate
BAY94-9392
type
DRUG
arm Group Labels
18F-FSPG and 18F-FDG Intragroup Comparision
description
Administered intravenously (IV)
name
18F-FDG
other Names
[18F]-Fluorodeoxyglucose ([18F]-FDG)
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

intervention Model Description

Intra-patient comparison of 2 different radiolabels

masking Info

masking: NONE

primary Purpose

DIAGNOSTIC

Enrollment

count: 7
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Standard Uptake Values (SUVs) for the radiotracers labels 18F-FSPG and 18F-FDG were assessed in tumor tissues of study participants, before (baseline), and after therapeutic treatment. Time frame was specified by protocol as at baseline, and at the time of clinical assessments during individual patient regular medical care. The time of the post-treatment assessment was not otherwise explicitly defined but could be anytime within 2 years. The outcome is reported as the difference of means from baseline to post-treatment (a number without dispersion), for all lesions for which an SUVmax value was assessed. A negative result indicates less uptake of radiotracer suggesting a small volume of tumor.
measure
Change From Baseline in Standard Uptake Value Maximum (SUVmax) Post-treatment
time Frame
Baseline and up to 2 years

secondary Outcomes

description
Safety and tolerability of 18F-FSPG and 18F-FDG were assessed as treatment-related adverse events, and reported as the number of events related to each treatment, without dispersion.
measure
Number of Treatment-Related Adverse Events
time Frame
Baseline to up to 2 years
description
Lesion size in centimeters (cm) were assessed in 2 dimensions from the computed tomography (CT) component of PET/CT and the area in cm2 calculated for lesion locations at baseline and after treatment. Time frame was specified by protocol as at baseline, and at the time of clinical assessments during individual patient regular medical care. The time of the post-treatment assessment was not otherwise explicitly defined but could be anytime within 2 years. The outcome is reported the difference in area in cm² for each lesion (a number without dispersion).
measure
Change From Baseline in Lesion Size Post-treatment, by 18F-FSPG or 18F-FDGs
time Frame
Baseline and up to 2 years

Full study description

brief Summary: The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.
detailed Description: OUTLINE: Patients are evaluated with a PET/CT scan using the radiolabel 18F-FSPG \[18F-(S)-4-(3-fluoropropyl)-L-glutamic acid\] or 18F-FDG (\[18F\]-fluorodeoxyglucose), before and after therapeutic treatment. PRIMARY OBJECTIVE: Uptake of the radiolabel 18F-FSPG in patients with biopsy-proven cancer will be evaluated and compared to the uptake of 18F-FDG, before and after therapy (non-specified) in the same group of patients. SECONDARY OBJECTIVES: * Compare the agreement of the clinical assessment for cancer status between 18F-FSPG and 18F-FDG. * Safety and tolerability of 18F-FSPG and 18F-FDG.

Source references

references

citation
Park P, Hatami N, Rutledge O, Koglin N, Loo B, Fan A, Mittra E. J Nucl Med. 58(suppl 1, no 118), 1 May 2017.
type
RESULT

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-8dd8753750dc68710a25
requested nct id
NCT02599194
primary nct id
NCT02599194
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Malignant+Mesothelioma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
payload sha256
ad2728fbf22b77801b61fcc66c7a71bf93d6a254a33747723e2f3a5688bd0d8b
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-8dd8753750dc68710a25
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT02599194
occurrences
context exact
NCT02599194
end
11
exact text
NCT02599194
start
0
offset unit
unicode_code_points
query cond
Malignant Mesothelioma
query disease state id
ds-malignant-mesothelioma
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-malignant-mesothelioma-000.json
source file sha256
0a018dbf1aa46f57978b6d16aa19b94d76d6d65cf1e297e889c8e599fef1fab1
source json pointer
/studies/59/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
d34344ea5dbf7589bb2c8401077ccafc2aad3de61964a7a5984588e9b21a95f0
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Malignant+Mesothelioma&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice